SCM
Sio Capital Management Portfolio holdings
AUM
$249M
This Quarter Return
-7.05%
1 Year Return
+117.71%
3 Year Return
+238.99%
5 Year Return
+411.91%
10 Year Return
+912.87%
AUM
$265M
AUM Growth
+$265M
(-7.6%)
Cap. Flow
+$3.81M
Cap. Flow
% of AUM
1.44%
Top 10 Holdings %
Top 10 Hldgs %
63.41%
Holding
63
New
13
Increased
11
Reduced
8
Closed
15
Top Buys
| 1 |
Teleflex
TFX
|
$16.2M |
| 2 |
Smith & Nephew
SNN
|
$14.4M |
| 3 |
Corbus Pharmaceuticals
CRBP
|
$10.2M |
| 4 |
VXRT
Vaxart
VXRT
|
$9.85M |
| 5 |
Abbott
ABT
|
$9.3M |
Top Sells
| 1 |
Globus Medical
GMED
|
$21.1M |
| 2 |
Cigna
CI
|
$16.3M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$13.6M |
| 4 |
Medtronic
MDT
|
$9.15M |
| 5 |
Embecta
EMBC
|
$7.77M |
Sector Composition
| 1 | Healthcare | 96.64% |
| 2 | Consumer Staples | 3.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Labcorp
LH
$23.1B
| $50M | 13.54% | 245,902 +20,000 | +9% | +$4.07M |
|
|
2
Teleflex
TFX
$5.59B
| $23.4M | 6.32% | 111,078 +77,200 | +228% | +$16.2M |
|
3
Zimmer Biomet
ZBH
$21B
| $16.9M | 4.56% | 155,304 +81,125 | +109% | +$8.8M |
|
|
4
Smith & Nephew
SNN
$16.3B
| $14.4M | 3.89% | +579,619 | New | +$14.4M |
|
5
Organon & Co
OGN
$2.45B
| $12.6M | 3.41% | 608,096 +129,073 | +27% | +$2.67M |
|
6
GSK
GSK
$79.9B
| $12M | 3.25% | 312,000 +48,555 | +18% | +$1.87M |
|
|
7
Corbus Pharmaceuticals
CRBP
$115M
| $10.2M | 2.76% | +225,165 | New | +$10.2M |
|
|
VXRT
8
DELISTED
Vaxart
VXRT
| $9.85M | 2.67% | +14,764,991 | New | +$9.85M |
|
9
Tyra Biosciences
TYRA
$675M
| $9.6M | 2.6% | 600,294 +64,553 | +12% | +$1.03M |
|
|
10
Abbott
ABT
$231B
| $9.3M | 2.52% | +89,500 | New | +$9.3M |
|
|
11
Cigna
CI
$80.3B
| $8.85M | 2.4% | 26,786 -49,300 | -65% | -$16.3M |
|
12
Kenvue
KVUE
$39.7B
| $8.82M | 2.39% | +485,000 | New | +$8.82M |
|
13
Disc Medicine
IRON
$2.07B
| $8.65M | 2.34% | +192,000 | New | +$8.65M |
|
14
Erasca
ERAS
$445M
| $6.78M | 1.84% | 2,874,536 +447,352 | +18% | +$1.06M |
|
15
Biodesix
BDSX
$62.6M
| $6.65M | 1.8% | +4,347,855 | New | +$6.65M |
|
16
Astria Therapeutics
ATXS
$349M
| $4.64M | 1.26% | 510,267 +100,000 | +24% | +$910K |
|
17
ANI Pharmaceuticals
ANIP
$2.03B
| $4.57M | 1.24% | 71,740 -15,614 | -18% | -$994K |
|
18
Bausch + Lomb
BLCO
$5.18B
| $4.4M | 1.19% | +302,710 | New | +$4.4M |
|
19
PMV Pharmaceuticals
PMVP
$74.2M
| $4.39M | 1.19% | +2,708,408 | New | +$4.39M |
|
20
Zymeworks
ZYME
$1.12B
| $4.18M | 1.13% | +491,128 | New | +$4.18M |
|
21
BridgeBio Pharma
BBIO
$9.89B
| $3.17M | 0.86% | 125,174 -78,000 | -38% | -$1.98M |
|
22
Apogee Therapeutics
APGE
$2.17B
| $3.07M | 0.83% | 78,000 | – | – |
|
23
Context Therapeutics
CNTX
$75.4M
| $2.66M | 0.72% | +1,328,352 | New | +$2.66M |
|
24
Modular Medical
MODD
$39.9M
| $2.43M | 0.66% | 1,539,352 | – | – |
|
25
Stoke Therapeutics
STOK
$1.08B
| $2.37M | 0.64% | 175,301 -50,195 | -22% | -$678K |
|